Managed Care Calendar
- AAPM 2010 Clinical Meeting
Poll
ACR Conference
Benefit of Golimumab on Radiographic Progression Reported in Psoriatic Arthritis
Philadelphia—Golimumab inhibited progression of radiographic damage to joints in patients with psoriatic arthritis (PSA), according to 52-week results of the randomized, controlled the GO-REVEAL (Golimumab-Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monoclonal Antibody) study reported at the ACR meeting. Arthur F. Kavanaugh, MD, of the University of California San Diego presented results a late-breaking news session.
Golimumab, an injectable anti-tumor necrosis factor (TNF
REQUIP XL is an oral dopamine agonist medication for Parkinson’s disease and had demonstrated significant improvement in the symptoms of Parkinson’s disease.
The Role of Immune Function in the Changing Landscape of RRMS Therapies
Gastroesophageal reflux disease (GERD) is an important
managed care health concern because it is one of the most common gastrointestinal (GI) disorders in the United
States. GERD affects nearly 18.6 million Americans, according to a national healthcare database analysis.
Parkinson’s disease (PD) is a progressive
and disabling neurologic disorder. The disease is the most prevalent type of parkinsonism, a clinical syndrome caused by lesions in the basal ganglia, predominantly in the substantia nigra, which produces deficits in motor behavior.
